On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Takes Part in Groundbreaking Genomes Project

Company: Predictive Oncology Inc. (POAI)
Category: Stock Spotlights

Predictive Oncology (NASDAQ: POAI) is a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments. An article discussing the company reads, “As part of Predictive Oncology’s commitment to determining the best pathways for more individualized and effective cancer treatment, one of its main subsidiaries – Helomics – partnered with the UK 100,000 Genomes Project (‘UK100K’) in a research study focused on driving precision medicine to help conquer ovarian cancer. The UK100K initiative couples whole-genome sequencing of National Health Service (NHS) patients with cancer and other diseases to rich clinical data on drug treatments and outcomes. Helomics’ study centers around utilizing this data to continue improving the effectiveness of its artificial intelligence (AI)-based precision oncology models to drive both the individualization of therapy (right drug for the right patient) as well as the discovery of new treatments. Over the long term, Helomics intends to seek approval to use its precision oncology models as part of the NHS for ovarian cancer treatment.”

To view the full article, visit http://nnw.fm/iW9k5

About Predictive Oncology Inc.

Predictive Oncology operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic and biotech industries; and second, production of the FDA-approved STREAMWAY(R) System for automated, direct-to-drain medical fluid disposal. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217